Jörn M. Schattenberg
A5090959657- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Diet, Metabolism, and Disease
- Liver Diseases and Immunity
- Hepatitis C virus research
- Diet and metabolism studies
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- Drug-Induced Hepatotoxicity and Protection
- Endoplasmic Reticulum Stress and Disease
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Lipid metabolism and disorders
- Hepatitis Viruses Studies and Epidemiology
- Gallbladder and Bile Duct Disorders
- Diabetes and associated disorders
- Drug Transport and Resistance Mechanisms
- Cell death mechanisms and regulation
- Pediatric Hepatobiliary Diseases and Treatments
- Folate and B Vitamins Research
- Metabolism, Diabetes, and Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
Johannes Gutenberg University Mainz
2016-2025
University Medical Center of the Johannes Gutenberg University Mainz
2016-2025
Saarland University
2023-2025
University Medical Center
2018-2025
Universitätsklinikum des Saarlandes
2024-2025
Methodist Hospital
2024
Sorbonne Université
2024
Texas Liver Institute
2024
Inserm
2024
Houston Methodist
2024
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis hepatocellular carcinoma globally. This burden is expected to increase as epidemics obesity, diabetes metabolic syndrome continue grow. The goal this analysis was use Markov model forecast NAFLD using currently available data.A used estimate NASH progression in eight countries based on data for adult prevalence obesity type 2 mellitus (DM). Published estimates expert...
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
Non-invasive fibrosis scores are widely used to identify/exclude advanced in patients with non-alcoholic fatty liver disease (NAFLD). However, these were principally developed and validated aged between 35 65 years of age. The objective this study was assess the effect age on performance non-invasive tests NAFLD.Patients recruited from European specialist hepatology clinics. cohort divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), ≥65 (n=76),...
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for the treatment of NASH fibrosis. Download PDF Research Summary. We are conducting ongoing phase 3 trial involving adults biopsy-confirmed and fibrosis stage F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned 1:1:1 ratio receive once-daily...
Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis NASH.
•Genome-wide association study involved 1,483 biopsied NAFLD cases and 17,781 controls.•Main analysis shows genome-wide significance for PNPLA3, TM6SF2, HSD17B13 GCKR.•Sub-analyses show near LEPR NASH PYGO1 steatosis.•Except GCKR, the significant signals were replicated. Background & AimsGenetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most studies (GWASs) have adopted radiologically assessed hepatic triglyceride content as...
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis and varying degrees of necroinflammation. Although chronic oxidative stress, inflammatory cytokines, insulin resistance have been implicated in the pathogenesis NAFLD, mechanisms that underlie initiation progression this remain unknown. c-Jun N-terminal kinase (JNK) activated oxidants cytokines regulates hepatocellular injury resistance, suggesting may mediate development steatohepatitis. The presence function JNK...
A 25-gene expression signature associates with progression of fibrosing steatohepatitis in independent NAFLD cohorts.
The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection early-stage HCC in patients with NASH have limitations. We assessed the ability GALAD score, which determines risk based on patient sex; age; and serum levels α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), des-gamma-carboxy prothrombin (DCP), to detect NASH.We performed a case-control study 125 (20% within Milan Criteria) 231 without (NASH controls)...
The PNPLA3 p.I148M, TM6SF2 p.E167K, and MBOAT7 rs641738 variants represent genetic risk factors for nonalcoholic fatty liver disease (NAFLD). Here we investigate if these polymorphisms modulate both steatosis fibrosis in patients with NAFLD. We recruited 515 NAFLD (age 16-88 years, 280 female patients). Liver biopsies were performed 320 patients. PCR-based assays used to genotype the PNPLA3, TM6SF2, variants. Carriers of alleles showed increased serum aspartate aminotransferase alanine...
Electronic health record (EHR)-based research allows the capture of large amounts data, which is necessary in NAFLD, where risk clinical liver outcomes generally low. The lack consensus on International Classification Diseases (ICD) codes should be used as exposures and limits comparability generalizability results across studies. We aimed to establish among a panel experts ICD that could become reference standard provide guidance around common methodological issues.Researchers with an...